stockrowSolventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
Follow SOLV
Alert me
Solventum Corporation (SOLV) Free cash flow
Solventum Corporation's free cash flow for fiscal 2025 was −$10.0M, compared with $805.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.00. Solventum Corporation ranks 32nd of 51 Medical Instruments & Supplies companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$10.0M | — |
| FY2024 | $805.0M | (50.46%) |
| FY2023 | $1.6B | 13.80% |
| FY2022 | $1.4B | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $97.0M | (32.64%) |
| Jun 2026 | $144.0M | — |
| Mar 2026 | −$273.0M | — |
| Dec 2025 | $32.0M | — |
| 12 more quarters | Free account |
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BAX Baxter International Inc. compare | $1.1B |
| COO The Cooper Companies, Inc. compare | $678.0M |
| ALGN Align Technology, Inc. compare | $644.5M |
| WST West Pharmaceutical Services, Inc. compare | $453.4M |
| AVTR Avantor, Inc. compare | $439.2M |
| ATR AptarGroup, Inc. compare | $295.0M |
| BLCO Bausch + Lomb Corporation compare | $252.0M |
| RGEN Repligen Corporation compare | $105.5M |
| SOLV Solventum Corporation | $0.00 |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on SOLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement